Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 16:15:20363613231211051.
doi: 10.1177/20363613231211051. eCollection 2023.

Talquetamab: A promising immunotherapy for multiple myeloma

Amna Tariq  1 , Abdul Wahid  2 , Fatima Asif  2 , Mahnoor Khan  2
Affiliations

Talquetamab: A promising immunotherapy for multiple myeloma

Amna Tariq et al. Rare Tumors. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Khanam R, Ashruf OS, Waqar H, et al. The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review. Antibodies 2023; 12(2): 38. - PMC - PubMed
    1. Landgren O, Nadeem O. Bispecific monoclonal antibodies in multiple myeloma: data from ASH 2022: A Podcast. Adv Ther. 2023; 40: 1–3. - PMC - PubMed
    1. Verkleij CP, Broekmans ME, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood advances 2021; 5(8): 2196–2215. - PMC - PubMed
    1. van de Donk NW, O’Neill C, de Ruijter ME, et al.. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. Curr Opin Oncol. 2023; 36(6): 10–97. - PMC - PubMed
    1. Tapia-Galisteo A, Álvarez-Vallina L, Sanz L. Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol 2023; 16(1): 83. - PMC - PubMed

LinkOut - more resources